{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:27Z","timestamp":1790960787735,"version":"4.1.0"},"reference-count":151,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Renal Association","id":[{"id":"https:\/\/ror.org\/01zpyjx73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The 2026 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease represents a substantial update, coming more than a decade since the previous KDIGO guideline on the topic. This time lapse was necessary in order to accumulate new scientific evidence that was meaningful for an updated guideline. The new guideline now includes updated recommendations and practice points for anaemia management, incorporating recent evidence on intravenous iron therapies and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This European Renal Best Practice commentary critically evaluates and comments on relevant and newer recommendations and practice points, focusing on key aspects from a European perspective. The new guideline emphasizes the need for a comprehensive evaluation of the patient at the time of diagnosis, to identify additional causes of anaemia other than erythropoietin insufficiency. Coherently, the timing and the type of treatment should be individualized. Moreover, it introduces more proactive thresholds for intravenous iron supplementation, especially for haemodialysis patients. Erythropoiesis-stimulating agents are recommended as the preferred first-line therapy due to persisting concerns regarding cardiovascular safety and methodological limitations of available HIF-PHI trials. The commentary includes considerations on special aspects not considered by the new KDIGO guideline, such as pregnancy, gender-specific considerations, and interactions with sodium-glucose cotransporter 2 inhibitors or inflammation. The commentary also highlights regional regulatory differences between European and US drug approvals for HIF-PHIs. While supporting most recommendations, European nephrologists should consider local contexts, regulatory approvals and emerging evidence when implementing these guidelines in clinical practice.<\/jats:p>","DOI":"10.1093\/ndt\/gfag014","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:12:00Z","timestamp":1769515920000},"page":"1554-1572","source":"Crossref","is-referenced-by-count":8,"title":["KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2323","authenticated-orcid":false,"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[{"name":"ASST Lariana Department of Nephrology and Dialysis, , Como ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-8184","authenticated-orcid":false,"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Hospital Cl\u00ednic , Barcelona ,","place":["Spain"]},{"name":"Anaemia Working Group of the Spanish Society of Nephrology ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-6233","authenticated-orcid":false,"given":"Michele F","family":"Eisenga","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Division of Nephrology, Department of Internal Medicine, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Dialysis and Internal Medicine, Medical University of Warsaw Department of Nephrology, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"University of Leicester Department for Cardiovascular Sciences, , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-245X","authenticated-orcid":false,"given":"Davide","family":"Bolignano","sequence":"additional","affiliation":[{"name":"University Magna Graecia of Catanzaro Department of Medical and Surgical Sciences, , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026092103514557700_bib1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"2026092103514557700_bib2","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"KDIGO Anemia Working Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026092103514557700_bib3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"2026092103514557700_bib5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2026092103514557700_bib7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"2026092103514557700_bib8","first-page":"5","article-title":"Nutritional anaemias: report of a WHO scientific group","volume":"405","author":"World Health Organization","year":"1968","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2026092103514557700_bib9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2026092103514557700_bib10","article-title":"Guideline on haemoglobin cutoffs to define anaemia in individuals and populations","year":"2024"},{"key":"2026092103514557700_bib11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bjhh.2017.03.007","article-title":"Tides within ourselves: how posture can affect blood volume, blood cells and clinical reasoning","volume":"39","author":"De Paula","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2026092103514557700_bib12","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib13","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026092103514557700_bib14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/ckj\/sfac240","article-title":"Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999-2018 National Health and Nutrition Examination Survey","volume":"16","author":"Kovesdy","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/ajcn\/nqab122","article-title":"Fewer US adults had low or transitional vitamin B12 status based on the novel combined indicator of vitamin B12 status compared with individual, conventional markers, NHANES 1999-2004","volume":"114","author":"Mineva","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"2026092103514557700_bib17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/biomedicines11041153","article-title":"Physiological associations between vitamin B deficiency and diabetic kidney disease","volume":"11","author":"Wu","year":"2023","journal-title":"Biomedicines"},{"key":"2026092103514557700_bib18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000189546","article-title":"Low serum vitamin B12 levels in chronic high-flux haemodialysis patients","volume":"75","author":"Chandna","year":"1997","journal-title":"Nephron"},{"key":"2026092103514557700_bib19","first-page":"e58751","article-title":"Serum vitamin B12 deficiency in chronic hemodialysis patients","volume":"16","author":"Mushtaq","year":"2024","journal-title":"Cureus"},{"key":"2026092103514557700_bib20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s41999-024-01093-9","article-title":"Prevalence, associated factors, and impact of vitamin B12 deficiency in older medical inpatients","volume":"16","author":"Papakitsou","year":"2025","journal-title":"Eur Geriatr Med"},{"key":"2026092103514557700_bib21","doi-asserted-by":"publisher","first-page":"e70045","DOI":"10.1111\/eci.70045","article-title":"Nutrition, cognition and chronic kidney disease: a comprehensive review of interactions and interventions","volume":"55","author":"Kanbay","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"2026092103514557700_bib22","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.3390\/molecules28237707","article-title":"New perspectives on circulating ferritin: its role in health and disease","volume":"28","author":"Fonseca","year":"2023","journal-title":"Molecules"},{"key":"2026092103514557700_bib23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ndt\/gfaa048","article-title":"The problem with transferrin saturation as an indicator of iron \u2018sufficiency\u2019 in chronic kidney disease","volume":"36","author":"Besarab","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026092103514557700_bib25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"ERA-EDTA ERBP advisory board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/hdi.12078","article-title":"TSAT is a better predictor than ferritin of hemoglobin response to epoetin alfa in US dialysis patients","volume":"18","author":"Gaweda","year":"2014","journal-title":"Hemodial Int"},{"key":"2026092103514557700_bib27","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s40620-024-02000-y","article-title":"Impact of transferrin saturation on cardiovascular events in non-dialysis-dependent chronic kidney disease patients treated with darbepoetin alfa","volume":"37","author":"Nakai","year":"2024","journal-title":"J Nephrol"},{"key":"2026092103514557700_bib28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajh.23682","article-title":"Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin","volume":"89","author":"Evstatiev","year":"2014","journal-title":"Am J Hematol"},{"key":"2026092103514557700_bib31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3324\/haematol.2019.245092","article-title":"Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats","volume":"106","author":"Jimenez","year":"2021","journal-title":"Haematologica"},{"key":"2026092103514557700_bib32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","article-title":"Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability","volume":"127","author":"Tang","year":"2020","journal-title":"Circ Res"},{"key":"2026092103514557700_bib33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41422-019-0260-6","article-title":"Transferrin plays a central role in coagulation balance by interacting with clotting factors","volume":"30","author":"Tang","year":"2020","journal-title":"Cell Res"},{"key":"2026092103514557700_bib34","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2022016410","article-title":"Hypoxia and low temperature upregulate transferrin to induce hypercoagulability at high altitude","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"2026092103514557700_bib35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14740\/jh1388","article-title":"Increased transferrin concentrations are not associated with thrombosis in people living at high altitude","volume":"14","author":"Amaru","year":"2025","journal-title":"J Hematol"},{"key":"2026092103514557700_bib36","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2021.07.013","article-title":"CRIC Study Investigators. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease","volume":"100","author":"Mehta","year":"2021","journal-title":"Kidney Int"},{"key":"2026092103514557700_bib37","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1681\/ASN.2016121350","article-title":"C-terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients","volume":"28","author":"Eisenga","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ekir.2025.01.029","article-title":"Systematic review of the effects of iron on cardiovascular, kidney, and safety outcomes in patients with CKD","volume":"10","author":"Chan","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib39","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092103514557700_bib40","doi-asserted-by":"publisher","first-page":"1285012","DOI":"10.3389\/fphar.2024.1285012","article-title":"Ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in patients with NDD-CKD: a systematic review and meta-analysis","volume":"15","author":"Ding","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026092103514557700_bib41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026092103514557700_bib42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib43","first-page":"65","article-title":"Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation","volume":"75","author":"Sari","year":"2017","journal-title":"Neth J Med"},{"key":"2026092103514557700_bib44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"2026092103514557700_bib45","doi-asserted-by":"publisher","first-page":"e2133935","DOI":"10.1001\/jamanetworkopen.2021.33935","article-title":"Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis","volume":"4","author":"Shah","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026092103514557700_bib46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","article-title":"A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status","volume":"22","author":"Bhandari","year":"2021","journal-title":"BMC Nephrol"},{"key":"2026092103514557700_bib47","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ekir.2023.05.002","article-title":"A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD","volume":"8","author":"Greenwood","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5334\/tohm.752","article-title":"Restless legs syndrome in chronic kidney disease- a systematic review","volume":"13","author":"Safarpour","year":"2023","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"2026092103514557700_bib49","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2003.11.021","article-title":"A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome","volume":"43","author":"Bernstein","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026092103514557700_bib50","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.12659\/MSM.900520","article-title":"Efficacy of intravenous iron sucrose in hemodialysis patients with restless legs syndrome (RLS): a randomized, placebo-controlled study","volume":"23","author":"Deng","year":"2017","journal-title":"Med Sci Monit"},{"key":"2026092103514557700_bib51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.sleep.2007.12.006","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome","volume":"10","author":"Earley","year":"2009","journal-title":"Sleep Med"},{"key":"2026092103514557700_bib52","doi-asserted-by":"publisher","first-page":"1503342","DOI":"10.3389\/fneur.2024.1503342","article-title":"Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis","volume":"15","author":"Khan","year":"2025","journal-title":"Front Neurol"},{"key":"2026092103514557700_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026092103514557700_bib54","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/ckj\/sfad105","article-title":"The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors","volume":"16","author":"Locatelli","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib55","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib57","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib58","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib59","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib60","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non\u2013dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib61","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv Ther"},{"key":"2026092103514557700_bib62","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib64","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib65","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.xkme.2023.100666","article-title":"Safety endpoints with vadadustat versus darbepoetin alfa in patients with non-dialysis-dependent CKD: a post hoc regional analysis of the PRO2TECT randomized clinical trial of ESA-na\u00efve patients","volume":"5","author":"Winkelmayer","year":"2023","journal-title":"Kidney Med"},{"key":"2026092103514557700_bib66","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/ndt\/gfac342","article-title":"Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials","volume":"38","author":"Singh","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib67","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMc2208182","article-title":"Daprodustat and on-treatment cardiovascular events in chronic kidney disease","volume":"387","author":"Rojas-Rivera","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib68","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1681\/ASN.0000000000000321","article-title":"Daprodustat and heart failure in CKD","volume":"35","author":"Cunningham","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib69","author":"Kyntra Bio"},{"key":"2026092103514557700_bib70","doi-asserted-by":"publisher","first-page":"795214","DOI":"10.3389\/fphar.2021.795214","article-title":"Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Xiong","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026092103514557700_bib71","doi-asserted-by":"publisher","first-page":"e0266243","DOI":"10.1371\/journal.pone.0266243","article-title":"The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials","volume":"17","author":"Abdelazeem","year":"2022","journal-title":"PLoS One"},{"key":"2026092103514557700_bib72","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.ajkd.2022.09.014","article-title":"Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis","volume":"81","author":"Zheng","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026092103514557700_bib73","doi-asserted-by":"publisher","first-page":"2313864","DOI":"10.1080\/0886022X.2024.2313864","article-title":"Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis","volume":"46","author":"Tian","year":"2024","journal-title":"Ren Fail"},{"key":"2026092103514557700_bib74","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026092103514557700_bib75","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/ckj\/sfac271","article-title":"The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis","volume":"16","author":"Takkavatakarn","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib76","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib77","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Chung","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092103514557700_bib78","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib79","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2215\/CJN.02730608","article-title":"Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis","volume":"4","author":"Parfrey","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092103514557700_bib80","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/tri.13885","article-title":"Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 \u00d7 2 factorial, open-label, randomized clinical trial","volume":"34","author":"Obi","year":"2021","journal-title":"Transpl Int"},{"key":"2026092103514557700_bib81","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1681\/ASN.2011060546","article-title":"Correction of postkidney transplant anemia reduces progression of allograft nephropathy","volume":"23","author":"Choukroun","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib82","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","article-title":"The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial","volume":"34","author":"Tsujita","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib83","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13643-024-02709-8","article-title":"A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin stimulating agents","volume":"13","author":"Chienwichai","year":"2024","journal-title":"Syst Rev"},{"key":"2026092103514557700_bib84","doi-asserted-by":"publisher","first-page":"27","DOI":"10.6002\/ect.2018.0283","article-title":"Treating posttransplant anemia with erythropoietin improves quality of life but does not affect progression of chronic kidney disease","volume":"18","author":"Pile","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"2026092103514557700_bib85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1440-1797.2005.00386.x","article-title":"Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients","volume":"10","author":"Cervelli","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"2026092103514557700_bib86","doi-asserted-by":"publisher","first-page":"1131516","DOI":"10.3389\/fendo.2023.1131516","article-title":"Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026092103514557700_bib87","doi-asserted-by":"publisher","first-page":"sfad143","DOI":"10.1093\/ckj\/sfad143","article-title":"Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials","volume":"17","author":"Minutolo","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib88","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/ndt\/gfad017","article-title":"Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients","volume":"38","author":"Cheng","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib89","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao","year":"2019","journal-title":"iScience"},{"key":"2026092103514557700_bib90","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12882-015-0138-x","article-title":"Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients","volume":"16","author":"Sibbel","year":"2015","journal-title":"BMC Nephrol"},{"key":"2026092103514557700_bib91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026092103514557700_bib92","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib93","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"2026092103514557700_bib94","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.34067\/KID.0000000808","article-title":"Association of different definitions of erythropoiesis-stimulating agent hyporesponsiveness with major adverse cardiovascular events: insights from ASCEND-D","volume":"6","author":"Mc Causland","year":"2025","journal-title":"Kidney360"},{"key":"2026092103514557700_bib95","doi-asserted-by":"publisher","first-page":"h2258","DOI":"10.1136\/bmj.h2258","article-title":"Management of anaemia in chronic kidney disease: summary of updated NICE guidance","volume":"350","author":"Padhi","year":"2015","journal-title":"BMJ"},{"issue":"1 Suppl 1","key":"2026092103514557700_bib96","first-page":"S182","article-title":"Practice guidelines for anemia of chronic kidney disease: update 2000","volume":"37","author":"NKF-K\/DOQI Clinical","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2026092103514557700_bib97","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib98","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to erythropoiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am J Nephrol"},{"key":"2026092103514557700_bib99","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12325-024-03015-4","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents in dialysis-dependent patients with anaemia of chronic kidney disease: a retrospective observational study","volume":"42","author":"Atzinger","year":"2025","journal-title":"Adv Ther"},{"key":"2026092103514557700_bib100","doi-asserted-by":"publisher","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"2026092103514557700_bib101","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1093\/jimmun\/vkaf167","article-title":"Roxadustat enhances inflammation and metabolic reprogramming in human leukocytes by affecting oxygen sensing","volume":"214","author":"Wrobeln","year":"2025","journal-title":"J Immunol"},{"key":"2026092103514557700_bib102","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/jcm14020303","article-title":"Efficacy and safety of roxadustat in patients with CKD: pooled analysis by baseline inflammation status","volume":"14","author":"Choukroun","year":"2025","journal-title":"J Clin Med"},{"key":"2026092103514557700_bib103","doi-asserted-by":"publisher","first-page":"e15310","DOI":"10.1016\/j.heliyon.2023.e15310","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: a systematic review and meta-analysis","volume":"9","author":"Zheng","year":"2023","journal-title":"Heliyon"},{"key":"2026092103514557700_bib104","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","article-title":"Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation","volume":"16","author":"Zhou","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026092103514557700_bib105","doi-asserted-by":"publisher","first-page":"3000605231204475","DOI":"10.1177\/03000605231204475","article-title":"Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients","volume":"51","author":"Song","year":"2023","journal-title":"J Int Med Res"},{"key":"2026092103514557700_bib106","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib107","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/jcpt.13696","article-title":"Addition of roxadustat to erythropoiesis-stimulating agent (ESA) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis","volume":"47","author":"Dai","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026092103514557700_bib108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin","year":"2015","journal-title":"Blood Purif"},{"key":"2026092103514557700_bib109","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"key":"2026092103514557700_bib110","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/ckj\/sfad152","article-title":"Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice","volume":"16","author":"Portol\u00e9s","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib111","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","article-title":"Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease","volume":"8","author":"Wu","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"2026092103514557700_bib112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/kidneydial5020023","article-title":"Risk factors associated with hyporesponsiveness to erythropoietin in chronic kidney disease patients on hemodialysis who present anemia: a multicenter case-control study","volume":"5","author":"Perez Tulcanaza","year":"2025","journal-title":"Kidney Dial"},{"key":"2026092103514557700_bib113","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.109988","article-title":"Hyporesponsiveness to erythropoietin-stimulating agents: possible solutions","author":"Yasin","year":"2023","journal-title":"Updates on Hemodialysis"},{"key":"2026092103514557700_bib114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000534701","article-title":"Proton pump inhibitors and hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients: results from the Japan dialysis outcomes and practice patterns study","volume":"55","author":"Nakashima","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026092103514557700_bib115","doi-asserted-by":"publisher","first-page":"20251155","DOI":"10.1515\/biol-2025-1155","article-title":"Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: a case report","volume":"20","author":"Liu","year":"2025","journal-title":"Open Life Sci"},{"key":"2026092103514557700_bib116","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1111\/ijlh.13325","article-title":"Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat","volume":"42","author":"Wu","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"2026092103514557700_bib117","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/sdi.12991","article-title":"Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease","volume":"34","author":"Wu","year":"2021","journal-title":"Semin Dial"},{"key":"2026092103514557700_bib118","doi-asserted-by":"publisher","first-page":"sfaf138","DOI":"10.1093\/ckj\/sfaf138","article-title":"Global, regional and national epidemiology of anemia attributable to chronic kidney disease, 1990\u20132021","volume":"18","author":"Liu","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026092103514557700_bib119","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.ekir.2023.07.032","article-title":"Regional variation in hemoglobin distribution among individuals with CKD: the ISN International Network of CKD Cohorts","volume":"8","author":"Canney","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib120","doi-asserted-by":"publisher","first-page":"gfaf221","DOI":"10.1093\/ndt\/gfaf221","article-title":"A longitudinal analysis of haemoglobin levels and major cardiovascular events","author":"Gall","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib121","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/ndt\/17.suppl_5.38","article-title":"Patient characteristics determining rHuEPO dose requirements","volume":"17","author":"Ifudu","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib122","article-title":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity","author":"WHO","journal-title":"Available at"},{"key":"2026092103514557700_bib123","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjh.16221","article-title":"UK guidelines on the management of iron deficiency in pregnancy","volume":"188","author":"Pavord","year":"2020","journal-title":"Br J Haematol"},{"key":"2026092103514557700_bib124","first-page":"e55","article-title":"Anemia in pregnancy","volume":"138","year":"2021","journal-title":"ACOG Practice Bulletin Obstet Gynecol"},{"key":"2026092103514557700_bib125","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41598-023-50234-w","article-title":"Clinical outcome post treatment of anemia in pregnancy with intravenous versus oral iron therapy: a systematic review and meta-analysis","volume":"14","author":"Pandey","year":"2024","journal-title":"Sci Rep"},{"key":"2026092103514557700_bib126","doi-asserted-by":"publisher","first-page":"120.e1","DOI":"10.1016\/j.ajog.2025.01.037","article-title":"Single-dose intravenous iron vs oral iron for treatment of maternal iron deficiency anemia: a randomized clinical trial","volume":"233","author":"Derman","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2026092103514557700_bib127","first-page":"e78326","article-title":"Comparing the treatment outcomes of oral and injectable iron therapies for anemia in pregnancy: a meta-analysis","volume":"17","author":"Qayyum","year":"2025","journal-title":"Cureus"},{"key":"2026092103514557700_bib128","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ekir.2024.01.015","article-title":"Anemia in pregnancy with CKD","volume":"9","author":"de Jong","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026092103514557700_bib129","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026092103514557700_bib130","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.nefroe.2024.03.011","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrologia (Engl Ed)"},{"key":"2026092103514557700_bib131","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ndt\/gfae198","article-title":"Canagliflozin and iron metabolism in the CREDENCE trial","volume":"40","author":"Koshino","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026092103514557700_bib132","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026092103514557700_bib133","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026092103514557700_bib134","doi-asserted-by":"publisher","first-page":"EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid"},{"key":"2026092103514557700_bib135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092103514557700_bib136","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026092103514557700_bib137","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026092103514557700_bib138","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-025-02685-6","article-title":"Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors","author":"Marques","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"2026092103514557700_bib139","doi-asserted-by":"publisher","first-page":"e007723","DOI":"10.1161\/JAHA.117.007723","article-title":"Association of hemoglobin concentration and its change with cardiovascular and all-cause mortality","volume":"7","author":"Lee","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026092103514557700_bib140","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/eurheartj\/ehae864","article-title":"Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","volume":"46","author":"Ferreira","year":"2025","journal-title":"Eur Heart J"},{"key":"2026092103514557700_bib141","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1182\/bloodadvances.2025016320","article-title":"Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females","volume":"9","author":"Doi","year":"2025","journal-title":"Blood Adv"},{"key":"2026092103514557700_bib142","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12933-025-02805-6","article-title":"Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study","volume":"24","author":"Lee","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026092103514557700_bib143","doi-asserted-by":"publisher","first-page":"e2517086","DOI":"10.1001\/jamanetworkopen.2025.17086","article-title":"Sodium-glucose cotransporter 2 inhibitors, erythrocytosis, and thrombosis in adults with type 2 diabetes","volume":"8","author":"Lewis","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092103514557700_bib144","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12933-025-02871-w","article-title":"Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study","volume":"24","author":"Mohamed","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026092103514557700_bib145","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41598-025-31726-3","article-title":"Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes","volume":"16","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"2026092103514557700_bib146","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.ajkd.2024.02.015","article-title":"Erythrocytosis and CKD: a review","volume":"84","author":"Aoun","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026092103514557700_bib147","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026092103514557700_bib148","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7326\/M19-2945","article-title":"Effects of interleukin-1\u03b2 inhibition on incident anemia: exploratory analyses from a randomized trial","volume":"172","author":"Vallurupalli","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026092103514557700_bib149","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib150","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD Stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026092103514557700_bib151","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1681\/ASN.0000000654","article-title":"Effects of clazakizumab on anemia and iron metabolism in patients with kidney failure","volume":"36","author":"Neuen","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag014\/66612420\/gfag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/8\/1554\/66612420\/gfag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/8\/1554\/66612420\/gfag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:52:05Z","timestamp":1789977125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/8\/1554\/8443332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":151,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag014","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,1,28]]}}}